Results 201 to 210 of about 21,302 (251)
Some of the next articles are maybe not open access.

Pharmacology of Leukotriene Receptor Antagonists

American Journal of Respiratory and Critical Care Medicine, 1998
Preclinical pharmacological studies have demonstrated that cysLT, receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. In vitro, these agents compete with [3H]LTD4 for binding to cysLT, receptors present on guinea pig and human lung cell membranes.
openaire   +2 more sources

Leukotriene receptor antagonists - an update

Drug and Therapeutics Bulletin, 2005
Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with ...
openaire   +2 more sources

Leukotriene receptor antagonists in chronic urticaria

Allergy, 2001
. SOME patients with chronic idiopathic urticaria (CIU) do not respond to antihistamines and require long-term steroid administration or even cyclosporin to control their disease. Recently, several studies reported good results with antileukotriene drugs in CIU (1–4); however, a prospective investigation aiming to detect which patients are more likely ...
R, Asero, A, Tedeschi, M, Lorini
openaire   +2 more sources

[Leukotriene antagonists].

Allergie et immunologie, 1999
Today, medicinal treatment of asthma over the long term is well codified and involves inhaled corticosteroid therapy, in association or not with beta 2-mimetic substances. Numerous studies have demonstrated the importance of leukotrienes in bronchoconstriction and in the delayed inflammatory reaction of asthma.
openaire   +1 more source

LEUKOTRIENES, LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA: AN UPDATE. PART II: CLINICAL STUDIES WITH LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA

Pharmacological Research, 1999
The demonstration that leukotrienes, mainly cysteinyl leukotrienes, have biological properties relevant to the pathogenesis of asthma has stimulated the development of many therapeutic compounds to block these deleterious effects. Two main classes of leukotriene modulators have been developed: CysLT1 receptor antagonists and leukotriene synthesis ...
P, Devillier, N, Baccard, C, Advenier
openaire   +2 more sources

Leukotriene Receptor Antagonists and Antiallergy Drugs

2016
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asthma (EIA).
Tsutomu, Tamada, Masakazu, Ichinose
openaire   +2 more sources

Leukotriene Receptor Antagonists

2022
Rui Zheng, Tian Yuan, Qintai Yang
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce   +2 more
exaly  

Leukotriene receptor antagonists. III. Pharmacological and chemical studies with LY137617, a leukotriene D4 and leukotriene E4 receptor antagonist.

Drugs under experimental and clinical research, 1989
A series of chlorophenoxyalkyl acids were prepared and evaluated as pharmacological antagonists of leukotriene D4. Structure-activity relationship studies pointed to LY137617 as a compound with possible therapeutic value. In experiments on isolated smooth muscles from the guinea-pig, this agent was a selective and moderately potent antagonist of ...
D K, Herron   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy